Barzin Y. Nabet
Genentech · 188 works · 8,292 citations · h-index 31
Top works
- Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
- Integrating genomic features for non-invasive early lung cancer detection
- Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
- Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
- Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
- Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
- Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
- Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
- Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification
- LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity
- The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
- Exosomes in the tumor microenvironment as mediators of cancer therapy resistance
- Inferring gene expression from cell-free DNA fragmentation profiles
- 1264MO IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)
- Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC
- Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
- Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
- KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition